Annual report pursuant to Section 13 and 15(d)

LICENSE AGREEMENTS (Details)

v3.22.2.2
LICENSE AGREEMENTS (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
Aug. 04, 2017
Jan. 31, 2022
Dec. 31, 2020
Jun. 30, 2022
XOMA (US) LLC [Member] | Xoma License Agreement [Member] | Upon Clinical and Regulatory Milestones | Maximum        
License Agreements        
Milestone closing payment       $ 35.0
XOMA (US) LLC [Member] | Xoma License Agreement [Member] | After Clinical and Regulatory Milestones | Maximum        
License Agreements        
Milestone closing payment   $ 185.0    
XOMA (US) LLC [Member] | Phase 2 Clinical Trial RZ358 | Xoma License Agreement [Member]        
License Agreements        
Milestone closing payment   2.0    
XOMA (US) LLC [Member] | Phase 3 Clinical Trial Rz 358 | Xoma License Agreement [Member] | Plan        
License Agreements        
Milestone closing payment   $ 5.0   5.0
ActiveSite Pharmaceuticals, Inc        
License Agreements        
Royalties percentage 2.00%      
ActiveSite Pharmaceuticals, Inc | Development And License Agreement [Member]        
License Agreements        
Milestone closing payment     $ 1.0  
ActiveSite Pharmaceuticals, Inc | Development And License Agreement [Member] | Plan | Maximum        
License Agreements        
Maximum Amount of Milestone Events $ 46.5      
ActiveSite Pharmaceuticals, Inc | Phase 2 Clinical Trial RZ402 | Development And License Agreement [Member] | Plan        
License Agreements        
Milestone closing payment       $ 3.0